De Rossi, Giulia http://orcid.org/0000-0001-6163-4590
Da Vitoria Lobo, Marlene E. http://orcid.org/0000-0001-5620-1010
Greenwood, John http://orcid.org/0000-0003-4496-2984
Moss, Stephen E. http://orcid.org/0000-0002-7304-8879
Funding for this research was provided by:
Diabetes UK
RCUK | Biotechnology and Biological Sciences Research Council
Wellcome Trust
RCUK | Medical Research Council
British Heart Foundation
Rosetrees Trust
Article History
Received: 9 September 2021
Revised: 22 September 2021
Accepted: 1 October 2021
First Online: 5 January 2022
Change Date: 28 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41433-022-01988-6
Competing interests
: JG and SM are founders and members of the scientific advisory board of a company spun out by UCL Business to commercialise a LRG1 function-blocking therapeutic antibody developed through the UK Medical Research Council DPFS funding scheme. JG and SM are shareholders of this company and named inventors on three patents related to LRG1 as a therapeutic target.